RxDoctor Payments Data

Redwan Asbahi, MD

Internal Medicine · Dearborn Heights, MINPI 1730445503

Payments from drug & device makers

$3,509in general payments, 2019–2025

Across 163 payments — averaging $21.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$881
  • Johnson & Johnson$250
  • Neurocrine Biosciences, Inc.$190
  • Novo Nordisk$156
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$100
  • plus $450 from 10 others

What the payments were for

  • Food & beverage$3,47999%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,509 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$133,504
Medicare patients
307
Services billed
1,590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban168$64,536
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$38,281
TrulicityDulaglutide33$33,212
FarxigaDapagliflozin Propanediol52$26,361
OzempicSemaglutide21$24,809
LinzessLinaclotide31$19,115
EntrestoSacubitril/Valsartan16$11,422
JardianceEmpagliflozin20$10,022
JanuviaSitagliptin Phosphate12$7,317
DapagliflozinDapagliflozin Propanediol12$5,146
Atorvastatin Calcium287$3,586
LokelmaSodium Zirconium Cyclosilicate13$3,077
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$2,945
Humalog Kwikpen U-100Insulin Lispro15$1,948
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$1,774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$68$64,536168 claims
GSKTrelegy Ellipta$1,483$38,28157 claims
Lilly USA, LLCTrulicity$96$33,21233 claims
AstraZenecaFarxiga, Lokelma$881$29,43765 claims
Novo NordiskOzempic$156$24,80921 claims
AbbVieLinzess$30$19,11531 claims
NovartisEntresto$31$11,42216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Dearborn Heights

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →